Schwarz Pharma has submitted an application for a Rotigotine transdermal patch, Neupro, for the treatment of patients with advanced stage Parkinson's disease to the European Medicines Agency(EMEA).
Neupro is a dopamine receptor-agonist innovatively formulated as a transdermal delivery system, a patch. The patch is applied once a day to the skin and releases Rotigotine continuously through the skin into the body for 24 hours. In February 2006, Neupro was approved for the treatment of early stage Parkinson's disease as monotherapy by the European Commission. Neupro, the Parkinson's patch has been launched in Germany, the UK and Austria with additional countries to follow.